Strekin AG Announces Completion of Patient Recruitment in the RESTORE Phase 3 Clinical Study of STR001 |
| September 12, 2019 | September 2019 Bond Updates |
|
BASEL, Switzerland, Sept. 12, 2019 /PRNewswire/ -- Strekin AG (www.strekin.com), a biopharmaceutical company focused on treatments for hearing loss, announced today that it has successfully completed patient recruitment in the RESTORE study, an international, randomized,... |
| View more at: https://www.prnewswire.com:443/news-releases/strekin-ag-announces-completion-of-patient-recruitment-in-the-restore-phase-3-clinical-study-of-str001-300915265.html |
| Related News |